Key Highlights
- Amazon One Medical introduced an integrated GLP-1 weight management service featuring virtual consultations, medication prescriptions, and pharmacy delivery.
- Pricing for insured patients begins at $25 monthly; self-pay injectable medications such as Wegovy and Zepbound are priced from $299 monthly.
- Amazon targets same-day medication delivery expansion to 4,500 cities nationwide by late 2026.
- Hims & Hers (HIMS) shares fell up to 6% during pre-market hours after the program was revealed.
- Bank of America analysts project Amazon’s entry could reduce HIMS’s GLP-1 revenue by 31%.
Amazon has entered the weight loss medication arena with significant force. The retail and technology giant announced on Tuesday the rollout of a comprehensive GLP-1 management service via Amazon One Medical, its healthcare division, integrating obesity treatment with pharmacy services and telemedicine appointments.
The initiative provides patients with branded weight loss drugs from major pharmaceutical companies, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. For those with insurance coverage, oral GLP-1 medications are available from $25 monthly. Cash-paying customers can obtain oral formulations starting at $149 per month, while injectable medications like Wegovy and Zepbound carry a $299 monthly starting price.
While these price points align with existing market rates, Amazon’s competitive advantage lies in operational efficiency — leveraging its delivery infrastructure for same-day service and creating a streamlined patient experience from initial evaluation through ongoing prescription management.
Tanvi Patel, VP and GM of Amazon Pharmacy, emphasized that the objective is simplifying adherence by ensuring medications “are delivered reliably directly to patients.”
The nationwide program treats weight management as an ongoing medical condition requiring sustained intervention rather than short-term treatment. Services encompass preliminary health screenings, organized medical consultations, continuous follow-up appointments, and clinically validated treatment approaches.
Patients can also access on-demand prescription renewals, with messaging consultations priced at $29 and video appointments at $49. Amazon’s roadmap includes extending same-day delivery capabilities to 4,500 urban areas by the conclusion of 2026.
HIMS Faces Competitive Pressure
The program launch significantly impacted Hims & Hers Health. HIMS shares declined as much as 6% during pre-market trading, though the decline moderated as the day progressed. The market response highlights mounting anxiety about Amazon’s incursion into the affordable GLP-1 segment where HIMS has established a foothold.
The development comes at a challenging moment for HIMS. The telehealth company has been pivoting toward branded obesity medications — representing the premium market segment — precisely when Amazon introduces a competing comprehensive offering. Bank of America analysts have cautioned this competitive dynamic could slash HIMS’s GLP-1 business by 31%.
Additional companies operating in the obesity pharmaceutical sector also experienced downward price movement Tuesday, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN).
Amazon’s Growing Presence in Weight Loss Medications
Tuesday’s announcement represents an evolution rather than Amazon’s initial foray into GLP-1 medications. The company introduced same-day delivery for Novo Nordisk’s Wegovy obesity medication in January. By April, it had incorporated same-day delivery for Eli Lilly’s newly approved weight-loss pill, Foundayo, through its online pharmacy platform.
The latest program consolidates these initiatives into a unified ecosystem — merging primary healthcare, pharmaceutical services, and telemedicine under one integrated platform.
Wall Street analysts maintain a Strong Buy consensus on AMZN with 45 analysts covering the stock — 42 rating it as a Buy and 3 as a Hold. The consensus price target of $286.74 suggests approximately 13% potential upside from present trading levels.
AMZN stock climbed approximately 1% in response to the announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
